Augmentin treatment during pregnancy and the prevalence of congenital abnormalities

A population-based case-control teratologic study

E. Czeizel, M. Rockenbauer, Henrik T. Sorensen, Jorn Olsen

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Objective: To study the human teratogenic potential of augmentin (amoxicillin+clavulanic acid) treatment during pregnancy. Materials and methods: Pair analysis of cases with different congenital abnormalities and their matched controls in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, between 1991 and 1996. Results: The case group included 6935 pregnant women who had offspring with congenital abnormalities, while the control group consisted of 10,238 pregnant women who had babies without any defects. The number (and rate) of pregnant women with augmentin treatment was 52 (0.75%) and 56 (0.55%) in the case and control groups, respectively (crude odds ratio (OR) with 95% confidence interval (CI) was 1.4, 0.9-2.0). The comparison of augmentin treatments during the second-third months of pregnancy (i.e. in the critical period for most major congenital abnormalities) in case-control pairs did not show a higher use of augmentin in any congenital abnormality group. Conclusion: Augmentin treatment of pregnant women in usual therapeutic doses is unlikely to increase the risk of congenital abnormalities in newborn infants. However, the number of cases and controls was limited, therefore, further multicenter-multinational studies are needed for the final risk assessment.

Original languageEnglish
Pages (from-to)188-192
Number of pages5
JournalEuropean Journal of Obstetrics Gynecology and Reproductive Biology
Volume97
Issue number2
DOIs
Publication statusPublished - 2001

Fingerprint

Amoxicillin-Potassium Clavulanate Combination
Case-Control Studies
Pregnancy
Pregnant Women
Population
Therapeutics
Control Groups
Multicenter Studies
Odds Ratio
Newborn Infant
Confidence Intervals

Keywords

  • Augmentin (amoxicillin+clavulanic acid)
  • Case-control analysis
  • Congenital abnormalities
  • Human teratogenic potential

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Reproductive Medicine

Cite this

@article{faa0d39dd6cc4a25b80c2beabcc6f510,
title = "Augmentin treatment during pregnancy and the prevalence of congenital abnormalities: A population-based case-control teratologic study",
abstract = "Objective: To study the human teratogenic potential of augmentin (amoxicillin+clavulanic acid) treatment during pregnancy. Materials and methods: Pair analysis of cases with different congenital abnormalities and their matched controls in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, between 1991 and 1996. Results: The case group included 6935 pregnant women who had offspring with congenital abnormalities, while the control group consisted of 10,238 pregnant women who had babies without any defects. The number (and rate) of pregnant women with augmentin treatment was 52 (0.75{\%}) and 56 (0.55{\%}) in the case and control groups, respectively (crude odds ratio (OR) with 95{\%} confidence interval (CI) was 1.4, 0.9-2.0). The comparison of augmentin treatments during the second-third months of pregnancy (i.e. in the critical period for most major congenital abnormalities) in case-control pairs did not show a higher use of augmentin in any congenital abnormality group. Conclusion: Augmentin treatment of pregnant women in usual therapeutic doses is unlikely to increase the risk of congenital abnormalities in newborn infants. However, the number of cases and controls was limited, therefore, further multicenter-multinational studies are needed for the final risk assessment.",
keywords = "Augmentin (amoxicillin+clavulanic acid), Case-control analysis, Congenital abnormalities, Human teratogenic potential",
author = "E. Czeizel and M. Rockenbauer and Sorensen, {Henrik T.} and Jorn Olsen",
year = "2001",
doi = "10.1016/S0301-2115(00)00545-5",
language = "English",
volume = "97",
pages = "188--192",
journal = "European Journal of Obstetrics and Gynecology and Reproductive Biology",
issn = "0028-2243",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Augmentin treatment during pregnancy and the prevalence of congenital abnormalities

T2 - A population-based case-control teratologic study

AU - Czeizel, E.

AU - Rockenbauer, M.

AU - Sorensen, Henrik T.

AU - Olsen, Jorn

PY - 2001

Y1 - 2001

N2 - Objective: To study the human teratogenic potential of augmentin (amoxicillin+clavulanic acid) treatment during pregnancy. Materials and methods: Pair analysis of cases with different congenital abnormalities and their matched controls in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, between 1991 and 1996. Results: The case group included 6935 pregnant women who had offspring with congenital abnormalities, while the control group consisted of 10,238 pregnant women who had babies without any defects. The number (and rate) of pregnant women with augmentin treatment was 52 (0.75%) and 56 (0.55%) in the case and control groups, respectively (crude odds ratio (OR) with 95% confidence interval (CI) was 1.4, 0.9-2.0). The comparison of augmentin treatments during the second-third months of pregnancy (i.e. in the critical period for most major congenital abnormalities) in case-control pairs did not show a higher use of augmentin in any congenital abnormality group. Conclusion: Augmentin treatment of pregnant women in usual therapeutic doses is unlikely to increase the risk of congenital abnormalities in newborn infants. However, the number of cases and controls was limited, therefore, further multicenter-multinational studies are needed for the final risk assessment.

AB - Objective: To study the human teratogenic potential of augmentin (amoxicillin+clavulanic acid) treatment during pregnancy. Materials and methods: Pair analysis of cases with different congenital abnormalities and their matched controls in the population-based dataset of the Hungarian Case-Control Surveillance of Congenital Abnormalities, between 1991 and 1996. Results: The case group included 6935 pregnant women who had offspring with congenital abnormalities, while the control group consisted of 10,238 pregnant women who had babies without any defects. The number (and rate) of pregnant women with augmentin treatment was 52 (0.75%) and 56 (0.55%) in the case and control groups, respectively (crude odds ratio (OR) with 95% confidence interval (CI) was 1.4, 0.9-2.0). The comparison of augmentin treatments during the second-third months of pregnancy (i.e. in the critical period for most major congenital abnormalities) in case-control pairs did not show a higher use of augmentin in any congenital abnormality group. Conclusion: Augmentin treatment of pregnant women in usual therapeutic doses is unlikely to increase the risk of congenital abnormalities in newborn infants. However, the number of cases and controls was limited, therefore, further multicenter-multinational studies are needed for the final risk assessment.

KW - Augmentin (amoxicillin+clavulanic acid)

KW - Case-control analysis

KW - Congenital abnormalities

KW - Human teratogenic potential

UR - http://www.scopus.com/inward/record.url?scp=0034947676&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034947676&partnerID=8YFLogxK

U2 - 10.1016/S0301-2115(00)00545-5

DO - 10.1016/S0301-2115(00)00545-5

M3 - Article

VL - 97

SP - 188

EP - 192

JO - European Journal of Obstetrics and Gynecology and Reproductive Biology

JF - European Journal of Obstetrics and Gynecology and Reproductive Biology

SN - 0028-2243

IS - 2

ER -